Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. - The deadline to move the Court to serve as lead plaintiff is December 15, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious malfunctions and risks to patient safety [5]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and sales halts [5]. - The firm claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5].

Core Viewpoint - The Life2000 ventilator by Baxter, initially seen as a promising product, has been permanently withdrawn from the market due to cumulative vulnerabilities and a significant digital security flaw, highlighting the risks associated with the digitalization of medical devices [1][17][24]. Group 1: Product Background and Initial Expectations - Baxter acquired Hillrom for $12.5 billion in 2021, with Life2000 symbolizing a key entry point into the home respiratory support market post-pandemic [3][5]. - The product was designed to meet a growing market need for portable home ventilators, aiming to be a new growth driver for Baxter [5][6]. Group 2: Series of Recalls and Issues - Life2000 faced three recalls: in 2023 for oxygen saturation issues, in 2024 for battery charging failures, and in 2025 for cybersecurity vulnerabilities [7][8][13]. - The initial oxygen saturation problem was perceived as a compatibility issue, but it indicated deeper systemic vulnerabilities [10]. - The battery failure posed a direct risk to patients relying on ventilation, leading to growing doubts about the device's reliability [12]. Group 3: Cybersecurity and Final Withdrawal - In 2025, serious cybersecurity vulnerabilities were discovered, including open debugging ports and lack of firmware integrity checks, which could allow unauthorized modifications [13][14]. - The device was classified as Class I (highest risk level) by the FDA, leading Baxter to choose market withdrawal over repairs due to the fundamental nature of the vulnerabilities [16][24]. Group 4: Industry Implications and Shifts - The failure of Life2000 reflects a broader industry shift where risks are no longer just mechanical or electrical but also involve software integrity and cybersecurity [17][21]. - The case emphasizes that in the digital healthcare era, the safety of life-support devices must consider whether parameters can be altered and if the software is trustworthy [22][24]. Group 5: Regulatory Changes and Future Considerations - The withdrawal coincided with the FDA's new cybersecurity regulations, which now require comprehensive security measures for medical devices throughout their lifecycle [28][29]. - The case serves as a warning for the industry, particularly for companies in China, about the importance of robust security systems as they expand into international markets [30][31][33]. Group 6: Conclusion and Future Outlook - The Life2000 incident encapsulates a new industry narrative: as medical devices become software-defined, their associated risks must be redefined [35][36]. - The future of medical technology will hinge on the ability to ensure software integrity, code verification, and overall system security [34][37].

Core Insights - Class actions have been initiated for stockholders of James Hardie Industries plc and Baxter International, Inc. with specific deadlines for lead plaintiff petitions [1] James Hardie Industries plc (NYSE:JHX) - The class period for the James Hardie lawsuit is from May 20, 2025, to August 18, 2025 [6] - Allegations include that James Hardie's North America Fiber Cement segment faced weakening demand due to distributor inventory destocking, which the company was aware of by April and early May 2025 [6] - The company falsely represented that demand remained strong and inventory levels were "normal" [6] - On August 19, 2025, a 12% sales decline in the segment was revealed, attributed to "normalization of channel inventories," leading to a share price drop of over 34% [6] Baxter International, Inc. (NYSE:BAX) - The class period for the Baxter lawsuit is from February 23, 2022, to July 30, 2025 [6] - Allegations state that the Novum LVP suffered systemic defects causing malfunctions, which exposed patients to serious risks [6] - Baxter was reportedly notified of multiple device malfunctions, injuries, and deaths related to these defects [6] - The company's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted [6] - There was a heightened risk that existing Novum LVPs would be taken out of service, and new sales would be paused, contradicting Baxter's statements about the product's safety and efficacy [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Baxter common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff is required to file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific issues included malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, which resulted in injuries and deaths [5] - Baxter's inadequate responses to these defects and the potential halting of new sales of the pumps contributed to misleading statements regarding the product's safety and sales prospects [5]

Core Viewpoint - Baxter International Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly suffered systemic defects leading to serious patient risks [6][8]. Group 1: Legal Proceedings - Faruqi & Faruqi, LLP is investigating potential claims against Baxter and has set a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in the class action lawsuit [3]. - The lawsuit claims that Baxter and its executives violated federal securities laws by failing to disclose critical information about the Novum LVP's defects and the associated risks to patients [6]. Group 2: Product Issues - The Novum LVP was reported to have systemic defects causing malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, which posed serious risks to patients [6]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [6]. Group 3: Market Impact - Following the announcement on July 31, 2025, regarding the voluntary pause of shipments and installations of the Novum LVP, Baxter's stock price fell by 22.4%, closing at $21.76 [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, about the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Baxter common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by December 15, 2025, to serve as lead plaintiff [3]. - The lawsuit alleges that Baxter misled investors regarding the safety and efficacy of its Novum LVP devices, which suffered systemic defects leading to serious risks for patients [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized as a leader in securities class action settlements [4].

Group 1 - Berger Montague is advising shareholders of Baxter International Inc. regarding an investigation into the Board of Directors for potential breaches of fiduciary duties related to the marketing and sale of the Novum Large Volume Pump [1] - The investigation focuses on whether the Board of Directors properly oversaw the marketing and sale of the Novum LVP, which is used for controlled delivery of intravenous fluids [1] - In July 2025, Baxter announced a voluntary and temporary pause in shipments and planned installations of the Novum LVP [1] Group 2 - Berger Montague is a prominent law firm specializing in complex civil litigation, class actions, and mass torts, with over $2.4 billion in post-trial judgments in 2025 [1] - The firm has recovered over $50 billion for clients and represented classes in various legal areas for over 55 years [1]

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Baxter International Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [1][3]. Summary by Sections Company Overview - Baxter International Inc. is a global company that develops, manufactures, and markets medical products used in hospitals and healthcare facilities [1]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [1]. - The lawsuit was filed on behalf of all investors who purchased or acquired Baxter's stock during this period [1]. Allegations Against Baxter - The complaint alleges that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Impact on Stock Price - On July 31, 2025, Baxter announced a suspension of all new Novum LVP sales, leading to a 22.4% drop in stock price, closing at $21.76 [4]. Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers by December 15, 2025, to serve as lead plaintiff [5]. - Shareholders can remain absent class members if they choose not to participate [5].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take existing Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].